In the guideline“Chinese expert consensus on imaging assessment of pancreatic ductal adenocarcinoma(PDAC)resectability”[1](DOI:10.1097/JP9.0000000000000199)published on pages of 1-7,volume 8 issue 1,the authors woul...In the guideline“Chinese expert consensus on imaging assessment of pancreatic ductal adenocarcinoma(PDAC)resectability”[1](DOI:10.1097/JP9.0000000000000199)published on pages of 1-7,volume 8 issue 1,the authors would like to add an additional funding source that was inadvertently omitted in the original publication.展开更多
A recently published study(Xin et al.,Prog Biochem Biophys,2026,53(2):431-441.DOI:10.3724/j.pibb.2025.0508)addresses the therapeutic challenges of pancreatic ductal adenocarcinoma(PDAC)by innovatively developing an or...A recently published study(Xin et al.,Prog Biochem Biophys,2026,53(2):431-441.DOI:10.3724/j.pibb.2025.0508)addresses the therapeutic challenges of pancreatic ductal adenocarcinoma(PDAC)by innovatively developing an orally administered nanogene delivery system.Designed to achieve in situ,efficient delivery of chimeric antigen receptor(CAR)genes to tumor sites,this approach offers a novel strategy for CAR-macrophage(CAR-M)based immunotherapy.Its key highlights are as follows.展开更多
文摘In the guideline“Chinese expert consensus on imaging assessment of pancreatic ductal adenocarcinoma(PDAC)resectability”[1](DOI:10.1097/JP9.0000000000000199)published on pages of 1-7,volume 8 issue 1,the authors would like to add an additional funding source that was inadvertently omitted in the original publication.
文摘A recently published study(Xin et al.,Prog Biochem Biophys,2026,53(2):431-441.DOI:10.3724/j.pibb.2025.0508)addresses the therapeutic challenges of pancreatic ductal adenocarcinoma(PDAC)by innovatively developing an orally administered nanogene delivery system.Designed to achieve in situ,efficient delivery of chimeric antigen receptor(CAR)genes to tumor sites,this approach offers a novel strategy for CAR-macrophage(CAR-M)based immunotherapy.Its key highlights are as follows.
